Complain about a product or service

Parkinson's Drugs Withdrawn Because of Heart Valve Damage

Permax and Generic Equivalents Being Withdrawn; Other Drugs Available

March 30, 2007

Drug Safety • Public Citizen Sues FDA for Failure to Act on Darvon • FDA Probes Arthritis Drug Link To Cancer • FDA Wants New Labeling Rules To Protect Pregnant, Nursing Women • Anti-Smoking Drug Chantix Linked to Seizures, Heart Problems, Diabetes • Bayer Pulls Trasylol From Market • MIT Researchers Confirm Contamination in Heparin • Be Careful Using Over-the-Counter Creams, Ointments • Another Heparin Producer Announces a Recall • FDA Moves Closer To Setting Up Shop In China • Study Raises Concerns About Anemia Drugs • Congress Hears Warnings about FDA • China Connection in Heparin Problems? • Heparin Linked to Severe Allergic Reactions • Antibiotic Leads to Tendon Ruptures • Second Safety Warning on Fentanyl Skin Patch • Merck Recalls Children's Vaccines • Study: Avandia May Do More Harm than Good • Texas Sues Drug Manufacturer Blamed for West Coast Deaths • Bayer Withdraws Antibleeding Drug Trasylol --- • More drug safety news ...

Manufacturers of pergolide drug products, which are used to treat Parkinson's disease, will voluntarily remove the drugs from the market because of the risk of serious damage to patients' heart valves.

The products being withdrawn are Permax, the trade name for pergolide marketed by Valeant Pharmaceuticals, and two generic versions of pergolide manufactured by Par and Teva.

Pergolide is in a class of medications called dopamine agonists and is used with levodopa and carbidopa to manage the symptoms (tremors and slowness of movement) of Parkinson's disease.

In 2006, an estimated 12,000 patients received prescriptions for pergolide from retail pharmacies in the United States. Patients taking pergolide should contact their doctors to discuss alternate treatments. Patients should not stop taking the medication, as stopping pergolide abruptly can be dangerous.

There are alternative therapies available for Parkinson's disease, including three other dopamine agonists that have not been associated with valvular heart disease. The removal of pergolide products is not expected to adversely affect patient care because of the alternative therapies available, the FDA said.

"Based on important new drug safety information, the U.S. Food and Drug Administration has been working with the manufacturers of pergolide products to voluntarily remove these drugs from the market," said Douglas Throckmorton, M.D., deputy director of FDA's Center for Drug Evaluation and Research. "The FDA's increased evaluation of post-market safety is benefiting the public because, in this case, as new data about the product became available, we were able to remove a less safe drug from the market."

Two recent New England Journal of Medicine studies confirm previous findings associating pergolide with increased chance of regurgitation (backflow of blood) of the mitral, tricuspid, and aortic valves of the heart.

Valve regurgitation is a condition in which valves don't close tightly, allowing blood to flow backward across the valve. Symptoms include shortness of breath, fatigue and heart palpitations.

In light of this additional post-market safety information, the companies that manufacture and sell pergolide will stop shipping pergolide for distribution and, in cooperation with FDA, will withdraw the products from the market.

Permax was approved in 1988 for Eli Lilly and Company as an adjunctive therapy with levodopa in Parkinson's disease. Valvular heart disease was first described in association with pergolide in 2002. In 2003, FDA asked Lilly to add valvulopathy (abnormality of cardiac valves) to the warnings section of Permax labeling, at which time a Dear Healthcare Practitioner letter was sent by Lilly. In 2006, the warning was upgraded to a black box warning, the FDA's strongest form of warning, because of new data concerning risks of heart valve damage.

FDA is issuing a Public Health Advisory (PHA) detailing the removal of pergolide products from the market. The PHA, which is available online includes information and recommended actions for physicians, pharmacists and patients.

The effect of the voluntary withdrawal on supplies of pergolide currently in pharmacies will not be immediate. This delay will allow time for health care providers and patients to discuss appropriate treatment options and time to change treatments.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.